> Chemicals & Drugs > Organic Chemical > Oxycontin

Oxycontin

Q: What are the common uses of Oxycontin?

Oxycontin is commonly prescribed to treat moderate to severe pain, particularly in chronic conditions like cancer pain, neuropathic pain, and severe arthritis. It is formulated to provide extended-release of the active ingredient oxycodone, allowing for long-lasting pain relief. Healthcare providers must carefully monitor patients when prescribing Oxycontin due to the high risk of addiction and abuse associated with this potent opioid medication.

Q: How can PubCompare.ai help with Oxycontin research?

PubCompare.ai's AI-powered platform can revolutionize Oxycontin research optimization. The tool helps researchers efficiently screen protocol literature from publications, pre-prints, and patents, while leveraging AI-driven comparisons to identify the most accurate and reproducible methods. This enhances research efficiency and reliability, allowing you to choose the best protocols for your specific Oxycontin-related research goals.

Q: What are the different variations or types of Oxycontin?

Oxycontin is primarily available in extended-release tablet form, which allows for the gradual and prolonged release of the active ingredient oxycodone. There are also immediate-release formulations of oxycodone available, but these are not considered Oxycontin. The extended-release nature of Oxycontin is what sets it apart and allows for its long-lasting pain relief properties.

Q: What are some common challenges with Oxycontin usage?

The primary challenge with Oxycontin is its high risk of addiction and abuse. This potent opioid medication must be used with caution, as it can lead to dependence and overdose if not properly managed. Patients may also experience side effects like drowsiness, constipation, and respiratory depression. Healthcare providers must carefully weigh the benefits and risks when prescribing Oxycontin and monitor patients closely for any signs of misuse or diversion.

Oxycontin is a potent opioid analgesic medication used to treat moderate to severe pain.
It contains the active ingredient oxycodone, which is derived from the opium poppy plant.
Oxycontin is formulated to provide extended-release of the drug, allowing for long-lasting pain relief.
It is commonly prescribed for chronic conditions such as cancer pain, neuropathic pain, and severe arthritis.
However, Oxycontin also carries a high risk of addiction and abuse, and has been the subject of widespread controversy and public health concerns.
Careful monitoring by healthcare providers is essential when prescribing Oxycontin to minimize the potential for misuse and overdose.

Most cited protocols related to «Oxycontin»

Opioid Prescription Patterns in Chronic Pain

Cited 13 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2010

acetaminophen - codeine AN 12 Analgesics Butorphanol Clinic Visits Darvon Demerol Dilaudid Drugs, Non-Prescription Duragesic Ethics Committees, Research Fentanyl Hydrocodone Hydromorphone Inpatient Levo-Dromoran Levorphanol Meperidine Methadone Morphine Nalbuphine Nubain Numorphan Opana Opioids Oxycodone Oxycontin Oxymorphone Pain Patients Pentazocine Percocet Propoxyphene Stadol Talwin Vicodin

Opioid and Benzodiazepine Prescribing Trends

Cited 6 times

Data on prescribing in 2012 come from IMS Health’s National Prescription Audit (NPA). NPA provides estimates of the numbers of prescriptions dispensed in each state based on a sample of approximately 57,000 pharmacies, which dispense nearly 80% of the retail prescriptions in the United States. Prescriptions, including refills, dispensed at retail pharmacies and paid for by commercial insurance, Medicaid, Medicare, or cash were included.*CDC used the numbers of prescriptions and census denominators to calculate prescribing rates for OPR, subtypes of OPR, and benzodiazepines. The OPR category included semisynthetic opioids, such as oxycodone and hydrocodone, and synthetic opioids, such as tramadol. It did not include buprenorphine products used primarily for substance abuse treatment rather than pain, methadone distributed through substance abuse treatment programs, or cough and cold formulations containing opioids. LA/ER OPR were defined as those that should be taken only 2 to 3 times a day, such as methadone, OxyContin, and Opana ER. High-dose OPR were defined as the largest formulations available for each type of OPR that resulted in a total daily dosage of ≥100 morphine milligram equivalents when taken at the usual frequency, for example, every 4–6 hours. Benzodiazepines included alprazolam, clonazepam, clorazepate, diazepam, estazolam, flurazepam, lorazepam, oxazepam, quazepam, temazepam, and triazolam.
CDC calculated prescribing rates per 100 persons for the United States, each census region, and each state. CDC described the distribution of state rates using mean, standard deviation (SD), coefficient of variation (CV) (SD divided by the mean), the interquartile ratio (IQ) (75th percentile rate divided by the 25th percentile rate), and the ratio of the highest/lowest rates. Rates were transformed into multiples of the SD above or below the mean state rate of each drug.

Paulozzi L.J., Mack K.A, & Hockenberry J.M. (2014). Vital Signs: Variation Among States in Prescribing of Opioid Pain Relievers and Benzodiazepines — United States, 2012. Morbidity and Mortality Weekly Report, 63(26), 563-568.

Full text: Click here

Publication 2014

Alprazolam Benzodiazepines Buprenorphine Clonazepam Clorazepate Common Cold Cough Diazepam Estazolam Flurazepam Hydrocodone Lorazepam Methadone Morphine Opana Opioids Oxazepam Oxycodone Oxycontin Pain Pharmaceutical Preparations Prescriptions quazepam Substance Abuse Temazepam Tramadol Triazolam

Comprehensive Psychiatric and Substance Assessment

Cited 5 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2013

Adult Alcoholic Intoxication, Chronic Alcohol Problem Amphetamines Antisocial Personality Disorder Anxiety Disorders Cocaine Dementia Diagnosis Disorder, Attention Deficit-Hyperactivity Eating Disorders Ethanol Gilles de la Tourette Syndrome Methamphetamine Mood Nervous System Disorder Nicotine Dependence Opiate Alkaloids Oxycontin Parent Pharmaceutical Preparations Process Assessment, Health Care Psychotic Disorders Schizophrenia Substance Abuse Detection Substance Use Urine

Identifying Drug Abuse Trends on Twitter

Cited 4 times

Phase 1 of the study first identified prescription drugs commonly abused by youth and adolescents using information available from the National Institute on Drug Abuse and developed keywords as filters that were then applied to the collection of Twitter data (see Figure 1 for keywords used and visual depiction of the data collection strategy) [20 ]. We used the identified drug’s generic/chemical/international nonproprietary name (eg, oxycodone) and brand name (eg, OxyContin, Percocet) in one set of data collected (ie, Generic Names), and the common “street” or “slang” names (eg, oxy, oxycotton) of drugs in another set of data collection (ie, Street Names) in order to optimize conversational data capture associated with NUPM promotion and behavior [21 (link),22 (link)]. Data were collected from the public Twitter Streaming API, and we applied the identified keywords/filters as endpoints in the data capture. This provided us with multiple raw JavaScript Object Notation (JSON) datasets of Twitter feeds and associated metadata for further analysis.
The study conducted an analysis of a 2-week subset of data collected and analyzed using this process from April 1-14, 2015 (ie, Study Data). The two separate datasets of tweets (one filtered for a drug’s generic name and a second for street names) were collected from the Twitter Streaming API using streamR package in R (CRAN), which was deployed on cloud-based computing services offered by Amazon Web Services (AWS) via Amazon EC2 t2.micro instances. In accessing the Twitter Streaming API, we used two different sets of Twitter apps, Consumer Keys (API Keys) and Consumer Secrets (API Secrets), in order to maximize data capture and lower the chance of hitting the Twitter Streaming API cap. The 2-week subset of data is part of a larger Twitter NUPM data mining project that has collected 3 months’ worth of data and that is undergoing separate analysis. AWS services were chosen due to their relative low cost (discussed below) and primarily for their stability in collecting, transferring, and storing data generated for this project. Specifically, the reliability of AWS (guaranteed availability of 99.95% for external connectivity) ensures contiguity of data when using multiple instances to collect data from the Twitter Streaming API.
R for streaming Twitter data was run on an RStudio Server preconfigured on an Amazon Machine Image (ami-45c72a01) originally developed and made freely accessible to the public (Louis Aslett’s RStudio Server Amazon Machine Image website). Streaming was scheduled to iteratively initiate and end every 24 hours, generating daily JSON files that included Twitter data filtered for prescription drug abuse keywords. In the event that streaming was interrupted for any reason, the script was written to automatically prompt the restart of the streaming collection process. The daily files were automatically transferred to a separate file storage server via SCP data transfer, and original files on the AWS server were deleted via SSH if the transfer was successful. Data analysis was performed on a local machine (Dell Precision T5810, 64GB memory, 4 CPU cores) or on an Amazon EC2 m4.4xlarge instance (64GB memory, 16 CPU cores). The R scripts and shell scripts used in this study are available from the first author's GitHub repository (TK).

Katsuki T., Mackey T.K, & Cuomo R. (2015). Establishing a Link Between Prescription Drug Abuse and Illicit Online Pharmacies: Analysis of Twitter Data. Journal of Medical Internet Research, 17(12), e280.

Full text: Click here

Publication 2015

Adolescent CTSB protein, human Generic Drugs Memory Oxycodone Oxycontin Percocet Pharmaceutical Preparations Prescription Drugs Youth

Latent Classes of Polydrug Use

Cited 4 times

We approached the analysis in two steps. First, we used LCA to identify latent classes of weekly polydrug use, based on patterns of drug type and route of administration. Second, we used logistic regression to identify demographic characteristics, HIV risk behaviors, and health outcomes that were associated with class membership. In this case, we used a combination of drug type (heroin, methamphetamine, prescription drugs, alcohol, and marijuana) and route of administration (injection, smoking, and swallowing) to define drug use profiles. In order to identify classes based on habitual (vs. episodic) use, we recoded each drug by specific route of administration into a binary variable (1 = used weekly or more frequently, 0 = used less than weekly or never). For example, heroin-injected, heroin-snorted, heroin-smoked were three separate variables coded as “used weekly or more” versus “less than weekly/never.” We then reviewed the distribution of drugs and selected drugs reported by at least 15% of the entire sample for inclusion in the LCA. Based on this standard, seven drug/administration-route combinations were included in the LCA: heroin injection, methamphetamine injection, methamphetamine smoking, methamphetamine snorting, prescription drug swallowing, binge drinking, and marijuana smoking. The prevalence of each drug assessed for inclusion in the model is depicted in appendix 1. Drugs not meeting inclusion criteria included: heroin smoke or snort; cocaine smoke, snort, or injection; simultaneous heroin & cocaine injection; simultaneous methamphetamine & cocaine injection; simultaneous methamphetamine & heroin injection; ketamine injection; oxycontin swallow, snort or injection; and prescription drug smoke, snort or injection.
We then examined models with between 2 and 5 classes. Fit statistics for each model are illustrated in Table 1. Smaller values of Akaike information criteria (AIC) and Bayesian information criteria (BIC) and higher values of entropy indicate better fit. A non-significant bootstrap likelihood-ratio test (LRT) P-value indicates that more classes does not improve the analysis (Gibson, 1959 ; Hagenaars & McCutcheon, 2002 ; McCuthcheon, 1987 ). Thus, we selected a two-class solution based on the goodness-of-fit indices.
After selecting the best fitting model, we used logistic regression to assess factors associated with class membership. Bivariate analyses were first conducted to determine demographic, behavioral, or health status indicators associated with class membership. Factors associated with class membership at the P < .20 level in bivariate analyses were considered for inclusion into a logistic regression model, using a manual backward stepwise approach. Variables achieving significance at the P < .05 level were retained in the final model. Models were checked for meaningful interactions and none were found to be statistically significant. Variables that produced a 10% or greater change between the crude and adjusted odds ratios were considered confounders and were retained in the final model regardless of their significance. All analyses were performed using SAS PROC LCA (Lanza, Dziak, Huang, Wagner, & Collins, 2012 ).

Roth A.M., Armenta R.A., Wagner K.D., Roesch S.C., Bluthenthal R.N., Cuevas-Mota J, & Garfein R.S. (2014). Patterns of Drug Use, Risky Behavior, and Health Status Among Persons Who Inject Drugs Living in San Diego, California: A Latent Class Analysis. Substance use & misuse, 50(2), 205-214.

Publication 2014

Cannabis sativa Cocaine Drug Combinations Entropy Ethanol Heroin Ketamine Methamphetamine Oxycontin Pharmaceutical Preparations Pharmacy Distribution Prescription Drugs Smoke

Most recents protocols related to «Oxycontin»

Pain Prevalence and Opioid Use

In this paper, we examined two outcomes, (1) experience of recurrent pain, measured by the question “Do you suffer from pain that occurs frequently?” (Yes/No), and (2) use of prescription opioids among those who responded “yes” to outcome 1, measured by the question “In the last 3 months, have you taken pain medications that require a prescription such as pain relievers that contain codeine or morphine (Fiorional, Tylex, Duramorf, Demerol, Durogesic, OxyContin, Codex, Percodan, Dimorf, Tramadol)?” (Yes/No). Due to a skip pattern in the questionnaire, we were not able to measure prescription opioid use in the full sample of participants, but only among those who reported pain based on question 1.

Mullachery P.H., Lima-Costa M.F, & de Loyola Filho A.I. (2023). Prevalence of pain and use of prescription opioids among older adults: results from the Brazilian Longitudinal Study of Aging (ELSI-Brazil). Lancet Regional Health - Americas, 20, 100459.

Full text: Click here

Publication 2023

Analgesics Codeine Demerol Duragesic Morphine Opioids Oxycontin Pain Percodan Pharmaceutical Preparations Tramadol

Opioid Use Disorder Treatment Experiences

A total of 40 participants (20 with OUD and 20 professionals) participated in the present study. Furthermore, 10 of the participants with OUD were Southern California residents before attending OUD treatment, and 10 participants with OUD were out-of-state residents before attending treatment in Southern California. Out-of-state residents came to Southern California to go to treatment and in most cases decided to live in Southern California. A combination of in-state and out-of-state residents were interviewed because a large percent of the SUD treatment population in Southern California came to treatment from out of the state.
Participants with OUD were eligible to participate in the current study if they had previously been in drug treatment at least once in Southern California after March of 2012. Further eligibility criteria for people with OUD were as follows: over the age of 18 at the time of the interview, opioids as the primary drug of use (e.g., heroin, OxyContin), self-reported misuse of opioids within the past 3 years, having health insurance at the time of treatment in Southern California, and English-speaking. Opioid misuse within the past 3 years was chosen to capture more recent use. Eligibility criteria for professionals were as follows: over the age of 18, work in the SUD treatment field, and English-speaking. Participants with OUD received $5 for participating in the current study, and no financial incentive was provided to professionals for participating in the study.

Clingan S.E., D’Ambrosio B.M, & Davidson P.J. (2023). Patient brokering in for-profit substance use disorder treatment: a qualitative study with people with opioid use disorder and professionals in the field. BMC Health Services Research, 23, 1214.

Full text: Click here

Publication 2023

Eligibility Determination Health Insurance Heroin Opioid Misuse Opioids Oxycontin Pharmaceutical Preparations Residential Treatment

Substance Use Patterns Across Social Groups

As this study aimed to detect differences between SU of different social groups rather than SU itself, substances were grouped into categories according to their general psychopharmacological mechanism of action (see Table 1 and [57 ]). In these categories, each person was assigned to the consumption quantity where the highest value of consumption for any of the queried substances within one group was reported.Table 1

Substance categories

Aggregation	Asked at age 17	Asked at age 20
Tobacco	Cigarettes, tobacco, shisha	Cigarettes, tobacco, shisha
Alcohol	beer, wine, mixed drinks	beer, wine, mixed drinks
Alcohol	Schnapps, vodka, whisky	Schnapps, vodka, whisky
Cannabis	Hashish, weed, cannabis, marijuana	Hashish, weed, cannabis, marijuana
Cannabis	n/a	synthetic cannabinoids (e.g., cannabis substitutes such as "Dutch Orange", "Spice", "K2", "Ganja Style")
Ecstasy/MDMA	Ecstasy, MDMA	Ecstasy, MDMA
Stimulants	Amphetamine, Speed, Pepp, Ice, Crystal Meth, Methamphetamine	Amphetamine or methamphetamine (e.g., "Speed", "Pepp", "Ice", "Crystal Meth")
Stimulants	Cocaine	Cocaine
Opioids	n/a	Cough syrups, pastilles or drops with codeine (e.g., Resyl plus®, Makatussin®, Pectocalmine N®, Codeine Knoll®)
Opioids	n/a	Opiate painkillers (e.g., Tramal®, Co-Dafalgan®, Sevredol®/Sevre-Long®, Subutex®, Oxycontin®, Palladon®, Durogesic®)
Benzodiazepines	n/a	Tranquillisers with benzodiazepines (e.g., Temesta®, Valium®, Rohypnol®, Xanax®, Dormicum®)
Hallucinogens	LSD, Psilocybe, magic mushrooms	LSD, Psilocybe, magic mushrooms
	n/a	2C-B or other "2C drugs" (e.g., "Bromo", "Erox", "Nexus", "Venus")
	n/a	Ketamine

In the survey, the participants were asked how often they had used a substance during the previous 12 months (excluding use of medications prescribed by a physician). Assessments were made on a six-point scale: 1 = ”never”, 2 = ”once”, 3 = ”2–5 times”, 4 = ”6–12 times (monthly)”, 5 = ”13–52 times (weekly)”, and 6 = ”53–365 times (daily)”. For measuring prevalence, we grouped the answers to used substances into three categories (aligning with [47 (link)]: “never” (1), “occasional” (2, 3, and 4) and “frequent” (5 and 6). Substances that fell under the category “frequent” in less than 10 participants were dichotomized to ensure the anonymity of the participants to “no-use” (1) and “use” (2, 3, 4, 5, and 6). For the following regression analyses, all substances were dichotomized to “no-use” vs. “use”.

Vock F., Johnson-Ferguson L., Bechtiger L., Stulz N., von Felten J., Eisner M., Hepp U., Ribeaud D., Shanahan L, & Quednow B.B. (2023). Substance use in sexual minority youth: prevalence in an urban cohort. Child and Adolescent Psychiatry and Mental Health, 17, 109.

Full text: Click here

Publication 2023

2-(4-(2-N-piperidino)ethoxyphenyl)-3-phenyl(2H)benzo(b)pyran Analgesics Benzodiazepines Cannabinoids Cannabis Codeine Dormicum Drug Kinetics Duragesic MDMA Methamphetamine Nexus Oxycontin Pharmaceutical Preparations Physicians Psilocybe Rohypnol Spices Subutex Temesta Tobacco Products Tramal Valium Wine Xanax

Substance Use, Overdose, and Craving

Past 30 days substance use. The measure assessed the use of multiple different forms of substances within the past 30 days, including tobacco, cannabis, other illicit drugs, and opioids such as heroin, methadone, morphine, OxyContin, codeine, fentanyl, oxycodone, hydrocodone, hydromorphone, and other opioid analgesics and pain killers. All variables were dichotomized as either yes or no.
Lifetime overdose. Overdoses were assessed by asking, “How many times have you overdosed on drugs?” Responses were collapsed into never versus at some point in lifetime.
Craving scale. Current craving for opioids was assessed using three items adapted from the Cocaine Craving Scale [14 (link)]. For each item, the score ranged from 0 to 10 and possible scale scores ranged from 0 to 30, with higher scores indicating a stronger craving.

Szlyk H.S., Constantino-Pettit A., Li X., Kasson E., Maranets E., Worku Y., Montayne M., Banks D.E., Kelly J.C, & Cavazos-Rehg P.A. (2023). Self-Identified Stage in Recovery and Substance-Use Behaviors among Pregnant and Postpartum Women and People with Opioid Use Disorder. Healthcare, 11(17), 2392.

Full text: Click here

Publication 2023

Analgesics Analgesics, Opioid Cannabis Cocaine Codeine Fentanyl Heroin Hydrocodone Hydromorphone Illicit Drugs Methadone Morphine Opioids Oxycodone Oxycontin Substance Use Tobacco Products

Prescription Opioid Use During Pregnancy

Consistent with prior research [8 (link), 9 , 34 (link)], any prescription opioid use is a dichotomous indicator of whether a respondent reported using any prescription opioids during their most recent pregnancy. Respondents were asked, “During your most recent pregnancy, did you use any of the following prescription pain relievers?”: (a) hydrocodone (like Vicodin®, Norco®, or Lortab®), (b) codeine (like Tylenol® #3 or #4, not regular Tylenol®), (c) oxycodone (like Percocet®, Percodan®, OxyContin®, or Ultracet®), (d) tramadol (like Ultram® or Ultracet®), (e) hydromorphone or morpheridine (like Demorol®, Exalgo®, or Dilaudid®), (f) oxymorphone (like Opana®), (g) morphine (like MS Contin®, Avinza® or Kadian®), or (h) fentanyl (like Duragesic®, Fentora®, or Actiq®). Respondents who answered affirmatively to using any of these prescription opioids during pregnancy were coded as a value of 1; those who did not indicate any use of these prescription opioids were coded as 0.

Testa A., Jacobs B., Zhang L., Jackson D.B., Ganson K.T, & Nagata J.M. (2023). Adverse childhood experiences and prescription opioid use during pregnancy: an analysis of the North and South Dakota PRAMS, 2019–2020. BMC Pregnancy and Childbirth, 23, 602.

Full text: Click here

Publication 2023

acetaminophen - codeine Analgesics Codeine Dilaudid Duragesic Fentanyl Fentora Hydrocodone Hydromorphone Morphine MS Contin Opana Opioids Oxycodone Oxycontin Oxymorphone Percocet Percodan Pregnancy Tramadol Tylenol Ultracet Ultram Vicodin

Top products related to «Oxycontin»

Propofol by B. Braun

Sourced in Germany

Propofol is an intravenous anesthetic agent used in medical procedures. It induces and maintains a state of unconsciousness and suppresses the body's response to surgical stimulation.

Spss statistics for windows version 23 by IBM

Sourced in United States, United Kingdom, Austria, Japan

SPSS Statistics for Windows, Version 23.0 is a software application for statistical data analysis. It provides a comprehensive set of tools for data management, analysis, and reporting.

Propolipid by Fresenius

Sourced in Finland, Sweden

Propolipid is a specialized lab equipment product. It is designed for the preparation and handling of lipid-based materials in a laboratory setting. The core function of Propolipid is to facilitate the precise and controlled manipulation of lipid-containing samples.

Ultiva by GlaxoSmithKline

Sourced in United Kingdom, Sweden, Belgium

Ultiva is a sterile, white to off-white, lyophilized powder for intravenous administration. Its active ingredient is remifentanil hydrochloride, a rapid-acting, potent opioid analgesic. Ultiva is indicated for the induction and maintenance of anesthesia and for the reduction of postoperative pain.

Lyrica by Pfizer

Sourced in United States, Japan

Lyrica is a laboratory equipment product used for the analysis and testing of various chemical and biological samples. It is designed to provide reliable and precise measurements to support research and development activities.

Sas 9 by SAS Institute

Sourced in United States, Austria, Japan, Belgium, United Kingdom, Cameroon, China, Denmark, Canada, Israel, New Caledonia, Germany, Poland, India, France, Ireland, Australia

SAS 9.4 is an integrated software suite for advanced analytics, data management, and business intelligence. It provides a comprehensive platform for data analysis, modeling, and reporting. SAS 9.4 offers a wide range of capabilities, including data manipulation, statistical analysis, predictive modeling, and visual data exploration.

Oxycodone hydrochloride by Daiichi Sankyo

Sourced in Japan

Oxycodone hydrochloride is a synthetic opioid analgesic. It is a white, crystalline powder with a bitter taste. Oxycodone hydrochloride is primarily used as a pain relief medication.

Nimbex by GlaxoSmithKline

Sourced in United Kingdom

Nimbex is a neuromuscular blocking agent used in anesthesia to facilitate endotracheal intubation and mechanical ventilation. It acts by blocking the action of acetylcholine at the neuromuscular junction, temporarily paralyzing the muscles.

D mannitol by Merck Group

Sourced in United States, United Kingdom, Germany, Canada, Spain, Italy, Japan, France

D-mannitol is a type of sugar alcohol commonly used in the production of pharmaceutical and laboratory equipment. It serves as a bulking agent, sweetener, and excipient in various formulations. D-mannitol is a white, crystalline powder with a sweet taste and is soluble in water. It is widely utilized in the pharmaceutical and biotechnology industries as a component in drug tablets, capsules, and other medicinal products.

What are the common uses of Oxycontin?

Oxycontin is commonly prescribed to treat moderate to severe pain, particularly in chronic conditions like cancer pain, neuropathic pain, and severe arthritis. It is formulated to provide extended-release of the active ingredient oxycodone, allowing for long-lasting pain relief. Healthcare providers must carefully monitor patients when prescribing Oxycontin due to the high risk of addiction and abuse associated with this potent opioid medication.

How can PubCompare.ai help with Oxycontin research?

PubCompare.ai's AI-powered platform can revolutionize Oxycontin research optimization. The tool helps researchers efficiently screen protocol literature from publications, pre-prints, and patents, while leveraging AI-driven comparisons to identify the most accurate and reproducible methods. This enhances research efficiency and reliability, allowing you to choose the best protocols for your specific Oxycontin-related research goals.

What are the different variations or types of Oxycontin?

Oxycontin is primarily available in extended-release tablet form, which allows for the gradual and prolonged release of the active ingredient oxycodone. There are also immediate-release formulations of oxycodone available, but these are not considered Oxycontin. The extended-release nature of Oxycontin is what sets it apart and allows for its long-lasting pain relief properties.

How can Oxycontin be used safely?

Careful monitoring by healthcare providers is essential when prescribeing Oxycontin to minimize the potential for misuse and overdose. Patients should follow their doctor's instructions precisely, take the medication only as directed, and report any concerning side effects or changes in their condition immediately. Proper storage and disposal of Oxycontin is also crucial to prevent accidental exposure or diversion.

What are some common challenges with Oxycontin usage?

The primary challenge with Oxycontin is its high risk of addiction and abuse. This potent opioid medication must be used with caution, as it can lead to dependence and overdose if not properly managed. Patients may also experience side effects like drowsiness, constipation, and respiratory depression. Healthcare providers must carefully weigh the benefits and risks when prescribing Oxycontin and monitor patients closely for any signs of misuse or diversion.

More about "Oxycontin"

Oxycontin, a powerful opioid analgesic medication, is used to manage moderate to severe pain.
Its active ingredient, oxycodone, is derived from the opium poppy plant and is formulated for extended-release, providing long-lasting pain relief.
Oxycontin is commonly prescribed for chronic conditions like cancer pain, neuropathic pain, and severe arthritis.
However, it carries a high risk of addiction and abuse, leading to widespread controversy and public health concerns.
Healthcare providers must carefully monitor Oxycontin prescriptions to minimize the potential for misuse and overdose.
Propofol, an anesthetic agent, and SPSS Statistics for Windows, a statistical analysis software, may be used in conjunction with Oxycontin for pain management and data analysis, respectively.
Propolipid, a lipid-based formulation, and Ultiva, a fast-acting opioid analgesic, are related pharmaceutical products.
Lyrica, an anticonvulsant medication, and SAS 9.4, a data analysis software, may also be utilized in the management of pain conditions.
Oxycodone hydrochloride, the active ingredient in Oxycontin, and Nimbex, a neuromuscular blocking agent, are other related substances.
D-mannitol, a sugar alcohol, may be used as an excipient in Oxycontin formulations.
Researchers can leverage PubCompare.ai's AI-powered platform to optimize their Oxycontin-related studies.
The tool helps locate protocols from literature, pre-prints, and patents, while utilizing AI-driven comparisons to identify the most accurate and reproducible methods.
This can enhance research efficiency and reliability, leading to improved understanding and management of Oxycontin's therapeutic and public health implications.